Charmaine Aguirre, MD
Family Medicine · Ponte Vedra Beach, FLNPI 1841599438
Payments from drug & device makers
Across 65 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$228
- Novo Nordisk$208
- GSK$139
- AstraZeneca$107
- Exact Sciences$102
- Pfizer$81
- plus $575 from 21 others
What the payments were for
- Food & beverage$1,440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $228 |
| Novo Nordisk | 6 | $208 |
| GSK | 3 | $139 |
| AstraZeneca | 6 | $107 |
| Exact Sciences | 6 | $102 |
| Pfizer | 4 | $81 |
| Lilly USA, LLC | 3 | $68 |
| Alnylam Pharmaceuticals Inc. | 2 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Amgen | 2 | $38 |
| Astellas Pharma US Inc | 2 | $36 |
| Corcept Therapeutics | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Antares Pharma, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Bayer | 1 | $14 |
| Corium, LLC | 1 | $13 |
| Medtronic | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$122
How this compares
$1,440 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $45,368 |
| OzempicSemaglutide | 27 | $33,455 |
| JanuviaSitagliptin Phosphate | 32 | $24,195 |
| JardianceEmpagliflozin | 25 | $20,794 |
| MounjaroTirzepatide | 17 | $18,338 |
| SynthroidLevothyroxine Sodium | 22 | $2,444 |
| Levothyroxine Sodium | 216 | $2,091 |
| Dexlansoprazole DrDexlansoprazole | 14 | $1,947 |
| Atorvastatin Calcium | 223 | $1,934 |
| Rosuvastatin Calcium | 107 | $1,558 |
| Losartan Potassium | 145 | $1,258 |
| Metoprolol Succinate | 95 | $1,068 |
| Colestipol Hcl | 12 | $1,033 |
| Lisinopril | 158 | $970 |
| Amlodipine Besylate | 162 | $953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $45,36834 claims |
| Novo NordiskOzempic | $208 | $33,45527 claims |
| Boehringer IngelheimJardiance | $24 | $20,79425 claims |
| Lilly USA, LLCMounjaro | $68 | $18,33817 claims |
| AbbVieSynthroid | $228 | $2,44422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ponte Vedra Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.